1 / 37

jnc 7 organizational structure

omer
Download Presentation

jnc 7 organizational structure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    2: Objectives

    3: Learning Objectives At the end of this presentation, participants will be able to- 1) appreciate the goals of anti-htn therapy 2) understand anti-htn choices

    5: HTN: management 52 yo male with no significant PMH comes for a physical check up and his BP was 160/90. What it is the target BP? What is the choice of therapy? Two months later 180/100? 54 yo male with PMH of HTN, DM, CKD(stage III) , goal BP? choice for the drug therapy? 70 you male with PMH of HTN, CAD, DM, LVSD(EF 30%)? Goal BP? Drug therapy?

    6: JNC 7

    7:

    8: BP Measurement

    9: Office BP Measurement

    10: Ambulatory BP Monitoring

    11: Self-Measurement of BP

    12: Blood Pressure Grades

    13: Benefits of Lowering BP

    14: Benefits of Lowering BP

    15: CVD Risk Factors

    16: CVD Risk

    17: Target Organ Damage

    18: Identifiable Causes of Hypertension

    19: Treatment Overview

    20: Goals of Therapy

    21: Lifestyle Modification: effect on BP

    22: Choice of drug therapy

    23: Algorithm for Treatment of Hypertension

    24: Followup and Monitoring

    25: Special Indications for Individual Drug Classes

    26: Special Indications for Individual Drug Classes

    27: Special indication: Left Ventricular Dysfucntion

    28: Hypertension in Older Persons

    29: Considerations in Antihypertensive Drug Choices

    30: Special consideration in Antihypertensive Drug Choices

    31: Summary

More Related